Proteasome inhibitor bortezomib ameliorates intestinal injury in mice

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Yanaba, Koichi ^a   Asano, Yoshihide ^a   Tada, Yayoi ^a   Sugaya, Makoto ^a   Kadono, Takafumi ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXTRAN SULFATE; DRINKING WATER; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; BORONIC ACID DERIVATIVE; ENZYME INHIBITOR; PROTEASOME; PYRAZINE DERIVATIVE;

ACUTE COLITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPLASM; DRUG EFFICACY; EXPERIMENTAL MODEL; GENE EXPRESSION; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; LYMPHOCYTE COUNT; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; ULCERATIVE COLITIS; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; INTESTINE; PATHOLOGY;

ANIMALIA; MURINAE; MUS;

ANIMALS; BORONIC ACIDS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COLITIS; DEXTRAN SULFATE; ENZYME INHIBITORS; INTERFERON-GAMMA; INTESTINES; MICE; MICE, INBRED C57BL; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 84859131427     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034587     Document Type: Article

References (32)

1. Fiocchi C, (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115: 182-205.
2. Hibi T, Ogata H, (2006) Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol 41: 10-16.
3. Sands BE, (2007) Inflammatory bowel disease: past, present, and future. J Gastroenterol 42: 16-25.
4. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, et al. (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702.
5. Cooper HS, Murthy SN, Shah RS, Sedergran DJ, (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249.
6. Melgar S, Karlsson A, Michaelsson E, (2005) Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 288: G1328-1338.
7. Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE, et al. (2000) Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion 62: 240-248.
8. King RW, Deshaies RJ, Peters JM, Kirschner MW, (1996) How proteolysis drives the cell cycle. Science 274: 1652-1659.
9. Ciechanover A, Schwartz AL, (1998) The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci USA 95: 2727-2730.
10. Baumeister W, Walz J, Zuhl F, Seemuller E, (1998) The proteasome: paradigm of a self-compartmentalizing protease. Cell 92: 367-380.
11. Adams J, (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349-360.
12. Richardson PG, Hideshima T, Anderson KC, (2003) Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 10: 361-369.
13. Yanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, et al. (2010) The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses. J Leukoc Biol 88: 117-122.
14. Neubert K, Meister S, Moser K, Weisel F, Maseda D, et al. (2008) The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14: 748-755.
15. Luo H, Wu Y, Qi S, Wan X, Chen H, et al. (2001) A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 72: 196-202.
16. Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, et al. (2004) Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 101: 8120-8125.
17. Blanco B, Perez-Simon JA, Sanchez-Abarca LI, Carvajal-Vergara X, Mateos J, et al. (2006) Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 107: 3575-3583.
18. Naujokat C, Daniel V, Bauer TM, Sadeghi M, Opelz G, (2003) Cell cycle- and activation-dependent regulation of cyclosporin A-induced T cell apoptosis. Biochem Biophys Res Commun 310: 347-354.
19. Coux O, Tanaka K, Goldberg AL, (1996) Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65: 801-847.
20. Schmidt N, Gonzalez E, Visekruna A, Kuhl AA, Loddenkemper C, et al. (2010) Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut 59: 896-906.
21. Visekruna A, Joeris T, Schmidt N, Lawrenz M, Ritz JP, et al. (2009) Comparative expression analysis and characterization of 20S proteasomes in human intestinal tissues: The proteasome pattern as diagnostic tool for IBD patients. Inflamm Bowel Dis 15: 526-533.
22. Visekruna A, Joeris T, Seidel D, Kroesen A, Loddenkemper C, et al. (2006) Proteasome-mediated degradation of IκBα and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest 116: 3195-3203.
23. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, et al. (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107: 4907-4916.
24. Naujokat C, Hoffmann S, (2002) Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest 82: 965-980.
25. Fissolo N, Kraus M, Reich M, Ayturan M, Overkleeft H, et al. (2008) Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur J Immunol 38: 2401-2411.
26. Vanderlugt CL, Rahbe SM, Elliott PJ, Dal Canto MC, Miller SD, (2000) Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J Autoimmun 14: 205-211.
27. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, et al. (1998) Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 95: 15671-15676.
28. Elliott PJ, Pien CS, McCormack TA, Chapman ID, Adams J, (1999) Proteasome inhibition: A novel mechanism to combat asthma. J Allergy Clin Immunol 104: 294-300.
29. Wirtz S, Neufert C, Weigmann B, Neurath MF, (2007) Chemically induced mouse models of intestinal inflammation. Nat Protoc 2: 541-546.
30. Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, et al. (1993) Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 38: 1722-1734.
31. Sato S, Ono N, Steeber DA, Pisetsky DS, Tedder TF, (1996) CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol 157: 4371-4378.
32. Meijerink J, Mandigers C, van de Locht L, Tonnissen E, Goodsaid F, et al. (2001) A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diag 3: 55-61.